Polysubstance Use Profiles Among the General Adult Population, United States, 2022
American Journal of Public Health · 2025
DOI: 10.2105/ajph.2024.307979 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Public Health, 2025. Verfasst von Karilynn M Rockhill und 3 weiteren Autor:innen. Beteiligte Einrichtung: Karilynn M. Rockhill and Alison Abraham are with the Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, CO. Karilynn…. Hauptthemen laut MEDLINE: Substance-Related Disorders, Recreational Drug Use. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.
Abstract (Originalsprache)
Objectives
To characterize present-day polysubstance use patterns in the general adult population.
Methods
From a 2022 nationally representative survey in the United States, we defined polysubstance use as last 12-month use of 2 or more drugs (n = 15 800). Latent class analyses included medical (as indicated) and nonmedical (not as directed) use of prescription opioids, stimulants, benzodiazepines, and antidepressants; recreational use of cannabis, psilocybin or mushrooms, other psychedelics, cocaine, methamphetamine, and illicit opioids; and concomitant use with alcohol, cannabis, prescriptions, or recreational drugs.
Results
The national prevalence of polysubstance use was 20.9% (95% confidence interval = 20.5%, 21.3%), broken down into the following 4 latent classes: (1) medically guided polysubstance use (11.5% prevalence, 6.1% substance use disorder [SUD]): prescribed drug use, some cannabis, and no concomitant use; (2) principal cannabis use variety (4.0% prevalence, 31.9% SUD): high probability of cannabis use with various drugs concomitantly used; (3) self-guided polysubstance use (3.4% prevalence, 14.5% SUD): nonmedical use of prescriptions and concomitant use; and (4) indiscriminate coexposures (2.1% prevalence, 58.9% SUD): concomitant drug use with indiscriminate drug preference.
Conclusions
Different polysubstance profiles show adults with untreated SUDs, and there are 2 previously unrecognized classes. Prevention and treatment strategies addressing polysubstance use should take a personalized perspective and tailor to individuals’ use profile. ( Am J Public Health. 2025;115(5):747–757. https://doi.org/10.2105/AJPH.2024.307979 )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Karilynn M. Rockhill and Alison Abraham are with the Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, CO. Karilynn M. Rockhill, Joshua C. Black, and Janetta Iwanicki are with Rocky Mou…
ORCID-Profile: Karilynn M Rockhill, Joshua C Black, Janetta Iwanicki, Alison Abraham
Förderung
- NIDA NIH HHS
Zitieren
APA
Rockhill, K. M., Black, J. C., Iwanicki, J., & Abraham, A. (2025). Polysubstance Use Profiles Among the General Adult Population, United States, 2022. American Journal of Public Health. https://doi.org/10.2105/ajph.2024.307979
Vancouver
Rockhill KM, Black JC, Iwanicki J, Abraham A. Polysubstance Use Profiles Among the General Adult Population, United States, 2022. American Journal of Public Health. 2025. doi:10.2105/ajph.2024.307979
BibTeX
@article{Rockhill2025,
author = {Rockhill, Karilynn M and Black, Joshua C and Iwanicki, Janetta and Abraham, Alison},
title = {Polysubstance Use Profiles Among the General Adult Population, United States, 2022},
journal = {American Journal of Public Health},
year = {2025},
doi = {10.2105/ajph.2024.307979}
}
EUVIMED